Swiss generics and biosimilars major Sandoz (SIX: SDZ) today presented its net sales update for the first quarter of 2025.

In a recent study conducted by Navaneethan and colleagues and published in the International Society of Nephrology, the ...

US-Ireland drugmaker Shorla Oncology has received approval from the US regulator for a new multi-dose vial of Tepylute ...

US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) today announced financial results for the first quarter of 2025, showing ...

The European Commission has approved the conversion of the conditional marketing approval (CMA) into a standard marketing ...

Pfizer reported first-quarter 2025 earnings on Tuesday that beat Wall Street expectations, boosted by ongoing cost-cutting ...

Shares of US clinical-stage biotech Biohaven (NYSE: BHVN) rose 9.6% to $21.74 yesterday, after it announced an agreement with ...

Italian pharma major Recordati (RECI: MI) has set new three-year financial targets for the period 2025-2027, aiming for ...

Early-stage biotech Nova Anchora has secured a new investment to move its lead therapy for epidermolysis bullosa (EB) closer ...

AstraZeneca posted a 10% rise in first-quarter revenue to $13.6 billion, supported by strong sales of cancer drugs and ...

Swiss pharma giant Novartis (NOVN: VX) this morning posted first-quarter 2025 financials, showing that net sales were $13.2 ...

Shares of French speciality vaccines developer Valneva (Nasdaq: VAL) were down 8.4% at 2.89 euros by early afternoon, after ...